Long-term complications of nucleoside reverse transcriptase inhibitor therapy

AIDS Reader

Volumn 13, Issue 4, 2003, Pages 176-187

  Dieterich, Douglas T ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Adverse effects, long term; HAART; Hepatotoxicity; HIV AIDS; Mitochondrial toxicity; Nucleoside reverse transcriptase inhibitors

Indexed keywords

ABACAVIR; AMPHOTERICIN B; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTIRETROVIRUS AGENT; CARNITINE; DIDANOSINE; EFAVIRENZ; FIBRIC ACID DERIVATIVE; GROWTH HORMONE; HYDROCHLOROTHIAZIDE PLUS TRIAMTERENE; LAMIVUDINE; METFORMIN; NELFINAVIR; OCTREOTIDE; PENTAMIDINE; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBOFLAVIN; RITONAVIR; SAQUINAVIR; STATINE; STAVUDINE; TENOFOVIR DISOPROXIL; THIAMINE; UBIQUINONE; UNINDEXED DRUG; VITAMIN B COMPLEX; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANEMIA; BLOOD TOXICITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG WITHDRAWAL; FATTY LIVER; HELLP SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LACTIC ACIDOSIS; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; MITOCHONDRIAL RESPIRATION; MORBIDITY; MORTALITY; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; PANCREATITIS; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; TREATMENT PLANNING;

ACIDOSIS, LACTIC; ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; LIVER; MITOCHONDRIA; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037631662     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.
2. White AJ. Mitochondrial toxicity and HIV therapy. Sex Transm Infect. 2001;77:158-173.
3. Brinkman K, Kakuda TN. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: a looming obstacle for long-term antiretroviral therapy? Curr Opin Infect Dis. 2000;13:5-11.
4. Martin JL, Brown CE, Matthews-Davis N, et al. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother. 1994;38:2743-2749.
5. Gaou I, Malliti M, Guimont MC, et al. Effect of stavudine on mitochondrial genome and fatty acid oxidation in lean and obese mice. J Pharmacol Exp Ther. 2001;297:516-523.
6. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in pyrimidine nucleoside combinations. In: Program and abstracts of the 3rd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; October 23-26, 2001; Athens, Greece. Abstract 18.
7. Côté H, Negredo E, Ruiz L, et al. Antiretroviral regimen-dependent mitochondrial DNA depletion in clinical samples from the SWATCH trial. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2002; Seattle. Poster 707-T.
8. John M, Mallal S. Hyperlactatemia syndromes in people with HIV infection. Curr Opin Infect Dis. 2002;15:23-29.
9. Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis. 2001;33:1931-1937.
10. John M, Moore CB, James IR, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS. 2001;15:717-723.
11. Gérard Y, Maulin L, Yazdanpanah Y, et al. Symptomatic hyperlactatemia: an emerging complication of antiretroviral therapy. AIDS. 2000;14:2723-2730.
12. Delgado J, Harris M, Tesiorowski A, et al. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis. 2001;33:2072-2074.
13. Marcus K, Truffa M, Boxwell D, et al. Recently identified adverse events secondary to NRTI therapy in HIV-infected individuals: cases from the FDA's Adverse Event Reporting System (AERS). In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2002; Seattle. Abstract LB14.
14. Coghlan ME, Sommadossi JP, Jhala NC, et al. Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases. Clin Infect Dis. 2001;33:1914-1921.
15. Brew B, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 9.
16. Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis. 2000;30:198-200.
17. Lenzo NP, Garas BA, French MA. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: a case report. AIDS. 1997;11:1294-1296.
18. Falcó V, Rodriguez D, Ribera E, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis. 2002;34:838-846.
19. US Department of Health and Human Services, Food and Drug Administration. FDA/Bristol Myers Squibb issues caution for HIV combination therapy with Zerit and Videx in pregnant women. January 5, 2001. Available at: http://aidsinfo.nih.gov. Accessed January 18, 2003.
20. Bristol-Myers Squibb. Important drug warning. January 5, 2001. Available at: www.fda.gov/medwatch. Accessed January 26, 2003.
21. Sarner L, Fakoya A. Acute onset lactic acidosis and pancreatitis in the third trimester of pregnancy in HIV-1 positive women taking antiretroviral medication. Sex Transm Infect. 2002;78:58-59.
22. Luzzati R, Del Bravo P, Di Perri G, et al. Riboflavine and severe lactic acidosis. Lancet. 1999;353:901-902.
23. Bristol-Myers Squibb. Important drug warning. February 2002. Available at: www.fda.gov/medwatch. Accessed January 26, 2003.
24. Wooltorton E. HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. CMAJ. 2002;166:1067.
25. Côté HCF, Montaner JSG. Editorial comment: management of lactic acidosis - an unresolved issue. AIDS Reader. 2002;12:223.
26. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther. 2000;22:911-936.
27. ter Hofstede HJM, de Marie S, Foudraine NA, et al. Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases. Int J STD AIDS. 2000;11:611-616.
28. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurement. AIDS. 2001;15:795-797.
29. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-166.
30. Pao D, Watson C, Peters B, et al. Hyperlactatemia and hepatic steatosis: mitochondrial toxicity of nucleoside reverse transcriptase inhibitors. Sex Transm Infect. 2001;77:381-384.
31. Côté HCF, Brumme ZL, Craib KJP, et al. Changes in the mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med. 2002; 346:811-820.
32. Fouty B, Frerman F, Reves R. Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet. 1998;352:291-292.
33. McComsey GA, Lederman MM. High doses of riboflavin and thiamine may help in secondary prevention of hyperlactatemia. AIDS Reader. 2002;12:222-224.
34. Posteraro AF, Mauriello M, Winter SM. Riboflavin treatment of antiretroviral induced lactic acidosis and hepatic steatosis. Conn Med. 2001;65:387-390.
35. Schramm C, Wanitschke R, Galle PR. Thiamine for the treatment of nucleoside-analogue-induced severe lactic acidosis. Eur J Anaesthesiol. 1999;16:733-735.
36. Arici C, Tebaldi A, Quinzan GP, et al. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. Int J STD AIDS. 2001; 12:407-409.
37. Brinkman K, Vrouenraets S, Kauffmann R, et al. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS. 2000;14:2801-2802.
38. Claessens YE, Cariou A, Chiche JD, et al. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS. 2000;14:472-473.
39. Lederman JC, Nawaz H. Toxic interaction of didanosine and acetaminophen leading to severe hepatitis and pancreatitis: a case report and review of the literature. Am J Gastroenterol. 2001;96:3474-3475.
40. Gisolf EH, Dreezen C, Danner SA, et al. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Clin Infect Dis. 2000;31:1234-1239.
41. Witt FW, Weverling GJ, Weel J, et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis. 2002;186:23-31.
42. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
43. Monforte AA, Bugarini R, Pezzoti P, et al, for the ICONA Study Group. Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr. 2001;28:114-123.
44. Dassopoulos T, Ehrenpreis ED. Acute pancreatitis in human immunodeficiency virus-infected patients: a review. Am J Med. 1999;107:78-84.
45. Aboulafia DM. Acute pancreatitis: a fatal complication of AIDS therapy. J Clin Gastroenterol. 1997;25:640-645.
46. Allaouchiche B, Duflo F, Cotte L, et al. Acute pancreatitis with severe lactic acidosis in an HIV-infected patient on ddI therapy. J Antimicrob Chemother. 1999;44:137-138.
47. Maxson CJ, Greenfield SM, Turner JL. Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome. Am J Gastroenterol. 1992;87:708-713.
48. Moore RD, Keruly JC, Chaisson RE. Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. AIDS. 2001;15:617-620.
49. Rodríguez-Rosado R, Pérez-Olmeda M, García-Samaniego J, et al. Management of hepatitis C in HIV-infected persons. Antivir Res. 2001;52:189-198.
50. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
51. Joly V, Flandre P, Meiffredy V, et al. Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naive for d4T and protease inhibitors (PI), and randomized between d4T/3TC/indinavir and AZT/3TC/indinavir (NORAVIR trial). In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 539.
52. Law M, Emery S, French M, et al. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomized controlled studies of combination antiretroviral therapy. In: Program and abstracts of the 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; September 13-15, 2000; Toronto. Abstract O28.
53. Molina JM, Angelini E, Cotte L, et al. Prevalence of lipodystrophy in the long-term follow-up of a clinical trial comparing various combinations of nucleoside analogue reverse transcriptase inhibitors (NRTI), ALBI trial (ANRS 070). In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco. Abstract 19.
54. Scarsella AJ, Dieterich DT, Graham NMH, et al. Predictors of lipodystrophy in HIV-infected patients from the CHORUS Observational Cohort. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2000; Toronto. Abstract 1286.
55. Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2002;29:21-31.
56. Gervasoni C, Ridolfo AL, Trifirò G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999; 13:465-471.
57. Saint-Marc T, Partisani M, Poizot-Martin I, et al. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco. Abstract 52.
58. Polo R, Verdejo J, Martinez S, et al. Contribution of NRTI combinations on lipodystrophy and impact of therapy switching. In: Program and abstracts of the 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; June 26-28, 1999; San Diego. Abstract 67.
59. John M, James I, McKinnon E, et al. A randomised, controlled, open-label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2002; Seattle. Poster 700-T.
60. McComsey G, Lonergan T, Fisher R, et al. Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2002; Seattle. Poster 701-T.
61. Carr A, Smith D, Workman C, et al and the MITOX Study Group. Switching stavudine or zidovudine to abacavir for HIV lipoatrophy: a randomised, controlled, open-label, multicentre, 24-week study. In: Program and abstracts of the 9th Conference on Retroviruses and Opportunistic Infections; February 22-25, 2002; Seattle. Abstract 32.
62. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000;59:1251-1260.
63. McArthur JC, Yiannoutsos C, Simpson DM, et al, and the AIDS Clinical Trials Group Team 291. A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. Neurology. 2000;54:1080-1088.
64. Simpson DM, Olney R, McArthur JC, et al. A placebo-controlled trial of lamotrigine for painful HIV-associated neuropathy. Neurology. 2000;54:2115-2119.
65. Cergnul I, Ernst J, Blum S, et al. Topical application of aspirin/diethyl ether in treatment of painful distal sensory polyneuropathy in HIV-positive individuals: a randomized, double-blind, crossover placebo-controlled study. In: Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections; February 4-8, 2001; Chicago. Abstract 601.
66. Famularo G, Moretti S, Marcellini S, et al. Acetylcarnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues. AIDS. 1997;11:185-190.
67. Hart AM, Terenghi G, Johnson M, et al. Immunohistochemical quantification of cutaneous innervation in HIV-associated peripheral neuropathy: a study of L-acetyl-carnitine therapy. In: Program and abstracts of the 3rd International Workshop on Salvage Therapy for HIV Infection; April 12-14, 2000; Chicago. Abstract 36.
68. Shlay JC. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: a randomized controlled trial. JAMA. 1998;280:1590-1595.
69. Kieburtz K, Simpson D, Yiannoutsos C, et al. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection. Neurology. 1998;51:1682-1688.
70. Simpson DM, Dorfman D, Olney RK, et al. Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. Neurology. 1996;47:1254-1259.
71. Paice JA, Shott S, Oldenburg FP, et al. Efficacy of a vibratory stimulus for the relief of HIV-associated neuropathic pain. Pain. 2000;84:291-296.
72. Weinberg RS, Chusid ED, Galperin Y, et al. Effect of antiviral drugs and hematopoietic growth factors on in vitro erythropoiesis. Mt Sinai J Med. 1998;65:5-13.
73. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
74. Semba RD, Shah N, Vlahov D. Improvement of anemia among HIV-infected injection drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:315-319.
75. Kline MW. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. Pediatrics. 1998;101:214-220.
76. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: overview of four clinical trials. Ann Intern Med. 1992;117:739-748.
77. Mudido PM, Georges D, Dorazio D, et al. Human immunodeficiency virus type 1 activation after blood transfusion. Transfusion. 1996;36:860-865.
78. Sloland E, Kumar P, Klein HG, et al. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: relationship to opportunistic infection. Transfusion. 1994;34:48-53.
79. Moore DA, Benepal T, Portsmouth S, et al. Etiology and natural history of neutropenia in human immunodeficiency virus disease: a prospective study. Clin Infect Dis. 2001;32:469-476.
80. Moore DA, Sullivan A, Hilstead P, et al. A retrospective study of neutropenia in HIV disease. Int J STD AIDS. 2000;11:8-14.
81. Mitsuyasu R. Prevention of bacterial infections in patients with advanced HIV infection. AIDS. 1999; 13(suppl 2):S19.
82. Kuritzkes DR, Parenti D, Ward DJ, et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. AIDS. 1998;12:65-74.
83. Hermans P, Rozenbaum W, Jou A, et al. Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection. AIDS. 1996; 10:1627-1633.
84. Filgrastim: new indication. AIDS-associated neutropenia: another soft indication. Prescrire Int. 2001; 10:106-107.
85. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:153-161.
86. Kelleher T, Cross A, Dunkle L. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine. Clin Ther. 1999;21:1182-1192.
87. Carey P. Peripheral neuropathy: zalcitabine reassessed. Int J STD AIDS. 2000;11:417-423.
88. Bartlett JG, Gallant JE. Antiretroviral therapy. In: Bartlett JG, Gallant JE. Medical Management of HIV Infection. Available at: http://hopkins-aids.edu/publications/book/ch4_agents_react.html. Accessed January 16, 2003.
89. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS. 1999;13:1659-1667.
90. Squires KE. An introduction to nucleoside and nucleotide analogues. Antivir Ther. 2001;6(suppl 3):1-14.
91. Scarsella A, Coodley G, Shalit P, et al. Stavudine-associated peripheral neuropathy in zidovudine-naive patients: effect of stavudine exposure and antiretroviral experience. Adv Ther. 2002;19:1-8.
92. Bartlett JG, Gallant JE. Management of opportunistic infections and other complications of HIV infection. In: Bartlett JG, Gallant JE. Medical Management of HIV Infection. Available at: http://hopkinsaids.edu/publications/book/ch5_main. html. Accessed January 16, 2003.